1Mountain CF. Revision in the International Syslem for Staging Lung Cancer. Chest, 1997, 111(6):1710
2Chemotherapy in non-small cell lung cancer: a meta analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ,1995,311(7010) =889
3Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely reseeted slage Ⅰ,Ⅱ,or Ⅲ A non small cell lung cancer. J Natl Cancer Inst, 2003, 95(19) :1453
4Arriagada R, Fergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non small cell lung cancer. N Engl J Med, 2004, 350(4):351
5Le Chevalier T, Dunant A, Arriagada R, et al. Long term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol, 2008, 26(20 Suppl) : A7507
6Winton T, Livingston R, Johnson I, et al. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med, 2005, 352 (25) : 2589
7Douillard J, Rosell R, Delena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patientswith completely resected stage IB-ⅢA non- small cell lung cancer (Adjuvant Navelbine International Trialist Association (ANITA): a randomised controlled trial. Lancet Oncol, 2006, 7(9): 719
8Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil tegafur for adenocarcinoma of the lung. N Engl J Med, 2004, 350(17) ;1713
9Hanlada C, Tanaka F, Ohta M, el al. Meta analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol, 2005, 23(22): 4999
10Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation (LACE) : a pooled analysis of five randomized clinical trials including 4,584 patients Proc Am Sue Clin Oncol, 2006, 24(18 Suppl) : 366s
同被引文献20
1Davidson JD,Ma L,Flagella M,etal.An increase in the expression of ribonucleotide reductase large subunit1is associated with gemcitabine resistance in non-small cell lung cancer cell lines[J].Cancer Res,2004,64(11):3761-3766.
2Gray J,Simon G,Bepler G.Molecular predictors of chemotherapy response in non-small-cell lung cancer[J].Expert Rev Anticancer Ther,2007,7(4):545-549.
3Schoenleber SJ,Kurtz DM,Talwalkar JA,etal.Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma:systematic review and meta-analysis[J].Br J Cancer,2009,100(9):1385-1392.
4The Cochrane Collaborative Review Group on HIV Infection and AIDS.Editorial policy:Inclusion and appraisal of experimental and non-experimental(Observational)studies.2009,available at:http://www.igh.org/Cochrane.Accessed May 20,2011.
5Lee JJ,Maeng CH,Baek SK,etal.The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1(RRM1)protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer(NSCLC)[J].Lung Cancer,2010,70(2):205-210.
6Rosell R,Scagliotti G,Danenberg KD,etal.Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer[J].Oncogene,2003,22(23):3548-3453.
8Su C,Zhou S,Zhang L,etal.ERCC1,RRM1and BRCA1mRNA expression levels and clinical outcome of advanced non-small cell lung cancer[J].Med Oncol,2011,28(4):1411-1417.
9Bepler G,Kusmartseva I,Sharma S,etal.RRM1-modulated in vitro and invivo efficacy of gemcitabine and platinum in non-small cell lung cancer[J].J Clin Oncol,2006,24(29):4731-4737.
10Bergman A,Eijk P,van Haperen V,etal.Invivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1as a major determinant[J].Cancer Res,2005,65(20):9510-9516.
